Advancements in biotechnology, RNAi-based therapeutics, and monoclonal antibody development are driving innovation. Expiring patents of originator biologics are accelerating biosimilar adoption, offering cost-effective alternatives. Regulatory support for biosimilars, increased healthcare spending, and patient demand for targeted therapies further fuel growth.
The report covers critical areas such asmarket trends, growth drivers, regional dynamics, and emerging opportunities,offering actionable insights to stay competitive. It also includes detailedforecasts segmented by therapeutic areas and technologies, enabling strategicplanning and informed decision-making. Backed by data-driven analysis andexpert insights, Cervicorn Consulting’s report is an essential resource fornavigating the complexities of the pharmaceutical market and identifyingavenues for sustained growth.
The shift from branded to generic drugs reduces the market share of originator companies and significantly impacts their revenue streams. The overall market dynamics are also affected by the pricing pressure brought on by these generics, forcing branded companies to reduce prices or find new market niches. This change is particularly evident in the biologics market, where patents for key products like Enbrel and Herceptin have expired, opening the door for cheaper alternatives. The Japan prescription drugs market is gaining momentum, supported by a rapidly aging population, a high incidence of chronic illnesses, and widespread access to universal healthcare. Japan’s advanced pharmaceutical innovation ecosystem and emphasis on personalized medicine are contributing to the adoption of targeted therapies, especially in oncology and neurology.
Industry Associations
The pharmaceuticalmarket is projected to surpass around USD 2.8 trillion by 2033, withtechnological innovations such as AI in drug discovery, precision medicine, anddigital health shaping its future. Employ our unique healthcare microsimulation model for market planning, scenario analysis and healthcare regulation solutions. Access World Markets Healthcare for the most comprehensive and up-to-date global outlook of the pharmaceutical industry.
IQVIA Patient Experience Solutions
Off-patent and off-exclusivity drugs refer to pharmaceutical products that have lost their patent protection or exclusivity rights. Generic drugs are typically more affordable than their brand-name counterparts and provide similar therapeutic effects. The availability of off-patent and off-exclusivity drugs contributes to increased accessibility to essential medications and competition in the pharmaceutical market. Artificial intelligence (AI) can play a vital role in developing novel generic drugs by suggesting excipients required for preparing a formulation. AI and machine learning (ML) algorithms can predict the pharmacokinetic and pharmacodynamic properties of generic drugs. Moreover, AI and ML can be incorporated into retail and hospital pharmacies to deliver correct medications to patients, decreasing medication dispensing errors.
US$ 84672 Billion
This makes it possible for researchers to create personalized treatments for particular patient populations. Artificial intelligence (AI) and machine learning (ML) technology have significantly accelerated the process of drug discovery and development, making the process more time and cost-effective. The machine-learning process involves creating a model based on past data to make predictions on future data. AI can aid many stages of drug discovery in many ways, including disease identification, target acquisition, computational screening, predicting drug toxicity, gene editing for developing gene therapies, and AI modeling for personalized drug dosing. In the U.S., generic pharmaceutical companies are responsible for manufacturing the medicines used in 9 out of 10 prescriptions that are dispensed.
The total prescription drug spending by the U.S. in 2022 was higher than other developed countries such as Australia (13.9 billion) and the U.K. Johnson & Johnson – Johnson & Johnson launched a cancer immunotherapy andexpanded its surgical robotics portfolio, focusing on AI-driven tools forimproved diagnostics and treatment planning. Click on data point to dive deeper into the details and uncover valuable insights about each segment.
There have been eight launches to date in 2023, compared to 11 launches for the same period in 2022, with oncology accounting for 38% of product launches in 2023. Food and Drug Administration (FDA) show evidence of launch based on supply in channels or active websites. Maximize your patient impact with expert guidance, data-driven insights, and a suite of cutting-edge patient data solutions. Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes. Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs. Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
What Is Covered Under Drugs For Immunotherapy Market?
Pharmaceutical companies that previously held a monopoly over theproduction of several crucial and life-saving medications are being encouragedto voluntarily give up their patents and provide local companies access tosecret formulations. Continued efforts to make generic formulationsaffordable for blockbuster drugs will ensure a steady pipeline of genericalternatives, leading to massive market growth. For the better understanding the recent situation of the global generic drugs market and for most policies of the country, Precedence Research forecast the future evolution of the generic drugs industry. This research study offers qualitative and measureable insights on generic drugs market and valuation of market size and development trends for global market segments. The high cost of branded oncology drugs can pose significant financial burdens on healthcare systems, insurers, and patients. Generic oncology drugs offer a more cost-effective alternative, helping to reduce overall healthcare expenditures and improve affordability and access to cancer treatments.
- Still, in the US, treatment coverage is estimated to be 28% and waiting times for treatment services can extend to several weeks 51.
- The average cost of a new prescription drug in the U.S. was USD 180,000 in 2021, fueling demand for OTC alternatives.
- Most working-age Americans get health insurance and prescription drug coverage from their employer.
- Based on molecule type, the market for conventional drugs (small molecules) dominated with a revenue share of 54.7% in 2024.
- Ongoing research, improved early detection methods, and innovative therapies further contribute to the segment’s market dominance.
What Made The Branded Drugs Segment Dominate The Market In 2024?
Cocaine use in the United States has declined substantially perhaps as a result of the falling price of methamphetamine. The significant decline in cocaine use is demand-driven since cocaine production has expanded substantially in the Andes over the last decade. Methamphetamine now is cheaper and more potent than the product that existed in the previous wave of the early 1990s. Fentanyl and methamphetamine have supplanted heroin and cocaine as the dominant drugs of policy concern. The report covers information about the list of market players and their latest development in the industry. The information includes mergers, partnerships, acquisitions, technological developments, and production lines.
- For instance, as per the Revised National Tuberculosis Control Programme Report, ~4.4 lakh patients died due to tuberculosis in India in 2018, i.e., 29% of the total 1.5 million deaths caused by the disease across the world.
- The increasing clinical trials for the development of orphan drugs and rising approval by regulatory agencies are anticipated to increase the uptake of these drugs during the forecast period and drive the market growth.
- Factors such as the expansion of retail and online pharmacies, regulatory approvals for prescription-to-OTC switches, and marketing initiatives contributed to market growth.
- The UK possesses strong R&D areas with expertise contributing to the development of novel drugs and therapies, generating impressive approaches for pharmaceutical companies.
- Moreover, the rise in prescription drug acquisition by hospitals owing to high demand and the increasing number of hospital pharmacies across the country is further driving the segment growth.
Top Companies In The Pharmaceutical Market
Technological integration in healthcare delivery and increased digital prescription usage are further stimulating market growth in both inpatient and outpatient settings. The United States Pharmaceuticals Market is segmented by product type, therapy area, distribution channel, route of administration, and end-user. By product type, the market is segmented into prescription drugs, generic drugs, OTC drugs, biologics, and biosimilars.
AI has a significant role in the respective market, as its algorithms assist in the drug discovery process from drug development, and in clinical trials in different phases. Also, it has various applications in the selection of trial design in clinical trials, including the selection of the right subjects for a specific trial, real-time data, and anticipation of trial outcomes, etc. Overall, AI-powered technologies are time-consuming, cost-effective, and enhance outcomes are influencing the market expansion. A rise in instances of several chronic diseases, accidents, or pandemic events, such as COVID-19, is boosting the demand for advanced drugs that are dispensed through hospital pharmacies. Nowadays, these hospital pharmacies are emerging in hubs to offer integrated chronic care support, particularly counseling and medication adherence monitoring, further enhancing their value and use.
Companies Mentioned
North America held the largest share of the drugs market which resulting in its dominance in the market in 2024. Numerous factors are contributing to the growth of the market, including a rapidly increasing number of patients with chronic diseases, like cardiovascular disease, diabetes, and cancer, which are leading to raised demand for drugs to manage these conditions. Moreover, accelerating technological advancements in drug delivery systems, such as mainly targeted therapies and biologics, are optimizing treatment potential and patient comfort.
These advancing technologies are further bolstering the widespread emergence of AI, nanotechnology, gene therapy, and cell therapy to foster discovery and evolve more targeted, efficient treatments. Furthermore, ongoing developments in tailored medicine are using varied biomarkers to find specific patient populations, resulting in more efficacious and targeted therapies. Regulatory authorities, including the FDA, EMA, and regional agencies, enforce comprehensive guidelines to ensure the safety, efficacy, and quality of pharmaceutical products.
Despite the availability of substitutes, pharmaceutical solutions retain demand due to proven efficacy, established clinical protocols, and broad applications across acute and chronic disease management. This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Branded generics, on the other hand, are given names to increase consumer recognition and loyalty. To improve the possibility of patients requesting it by name, it is referred to as Cryselle rather than its generic name (norgestrel and ethinyl estradiol). To achieve cost savings, formulary administrators must examine the drugs on their formularies regularly.
The Next Decade: Key Trends Defining The Future Market
This increasing initiatives into rare diseases therapies are attributable to the fact that the development of blockbuster drugs is possible in orphan diseases as compared to the already mature markets of other traditional diseases such as cardiovascular and diabetes. The above factors, combined with the need for efficient therapeutics for severely debilitating rare diseases, are further projected to fuel the demand for these types of prescription products and boost the global market growth. Several regions across the globe faced challenges in accessing medical care and treatment due to the escalation of country restrictions or lockdowns. These factors also limited the number of patient visits to hospitals, and the dispersion of prescriptions by healthcare professionals, further moderately limiting the demand and adoption of prescription drugs.
